Goldman Sachs analyst Ziyi Chen upgraded Luye Pharma (LYPHF) to Neutral from Sell with a HK$3.13 price target The firm believes the downside risks have been largely reflected in the stock’s valuation.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LYPHF: